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CRISPR-Cas systems have immense biotechnological
utility. A recent study reveals the potential of the Cpf1
nuclease to complement and extend the existing
CRISPR-Cas9 genome-editing tools.
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Bacteriophage resistancespacer sequences. Finally, in ‘interference’ the crRNA in
complex with Cas proteins uses the spacer to recognizePhage resistance provides ‘biotech bounty’
In the 100 years since their discovery, bacteriophages
have significantly shaped our understanding of funda-
mental biological processes, including those pertinent
to the central dogma of molecular biology, and have
‘gifted’ us their enzymes (including T4 ligase and T7
RNA polymerase) as biotechnological tools [1]. In
addition, studies of phage–bacterium interactions have
uncovered a diverse range of resistance mechanisms [2],
which have provided further reagents, including restric-
tion enzymes and CRISPR-Cas (clustered regularly inter-
spaced short palindromic repeat-CRISPR associated)
systems [1–3]. The CRISPR-Cas systems, in particular
the Cas9 protein, have captured the imagination of re-
searchers because they provide highly programmable
systems that have a wide array of molecular biology
applications [3]. In a recent Cell article, the Zhang
laboratory and their collaborators have added a new
Cas protein, Cpf1, to this biotechnological arsenal [4].
CRISPR-Cas systems endow prokaryotes with an adap-
tive immunity against phages and other mobile genetic
elements, such as plasmids [1–3]. These systems are
widespread, found in half of bacteria and most archaea,
and they are evolutionarily diverse [5]. Makarova and
colleagues recently refined the classification of CRISPR-
Cas systems and proposed two major classes incorporat-
ing five types of system, which are further categorized* Correspondence: peter.fineran@otago.ac.nz
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been studied in detail (the class 1 types I and III and the
class 2 type II (Cas9) systems) [5]. CRISPR-Cas systems
function in three steps. First, ‘adaptation’ involves the
addition of invader DNA as a ‘spacer’ into the CRISPR
array — the ‘memory’. Second, during ‘expression’ the
CRISPR array(s) are transcribed and processed to form
guide CRISPR RNAs (crRNAs) consisting of repeat and
a sequence termed a protospacer and degrades the target
nucleic acids. The characterization of Cpf1 demonstrates
for the first time that the type V class 2 systems are
functional CRISPR-Cas systems [4].
The type II systems, consisting of the Cas9 interfer-
ence protein and two RNAs (a trans-activating crRNA
(tracrRNA) and the crRNA) are ‘streamlined’ relative to
the multi-protein type I and III interference complexes
[6]. This simplicity, and the ability to replace the two
RNAs with an engineered single guide RNA (sgRNA),
led the Charpentier and Doudna groups to propose Cas9
for genome editing [6]. In the past three years, immense
academic and commercial interest has pushed the tech-
nology from a concept to a widely used molecular biology
tool [3]. Cas9 can be RNA-guided to target DNA in a
sequence-specific manner and catalyzes double-stranded
breaks (DSBs) (Fig. 1). The blunt DSBs are formed by two
separate nicks, catalyzed by the RuvC- and HNH-like
domains present in Cas9, instigating host-mediated DNA
repair that can be exploited to facilitate mutant generation
[3]. In addition, catalytically inactive Cas9 can be localized
without DNA cleavage for multiple applications, such as
the repression or activation of gene expression or imaging
[3]. The broad applicability of CRISPR-Cas9 has allowed
genetic manipulation in a huge variety of organisms, in-
cluding viruses, bacteria and eukaryotes. Despite rapid
advances, this nascent technology has scope for im-
provement, and Cpf1 may offer further progress [4].icle is distributed under the terms of the Creative Commons Attribution 4.0
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Fig. 1 Schematic comparison of target recognition and degradation by Cpf1 and Cas9. An R-loop is formed as a result of protospacer adjacent motif
(PAM) recognition (yellow), and subsequent base-pairing interactions occur between the CRISPR RNA (crRNA) and its cognate target sequence. Note
that the guide RNA in Cas9 is an RNA duplex involving crRNA and trans-activating CRISPR RNA (tracrRNA), whereas Cpf1 uses a single crRNA.
Upon sufficient complementarity in the seed region (red), Cpf1 and Cas9 nucleases will make two single-stranded cuts (blue triangles) resulting
in a double-stranded break. DNA and crRNA lengths and cleavage positions are schematic only and are not drawn to scale
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Schunder and colleagues identified the cpf1 and cas
genes, with their associated CRISPR arrays, in Franci-
sella spp. and suggested that they were functional due to
the presence of spacers that are similar to prophages [7].
Makarova et al. [5] subsequently proposed a new classifi-
cation for CRISPR-Cas systems that included the type V
CRISPR-Cas systems, which are characterized by the Cpf1
‘signature’ protein. Zetsche et al. [4] tested the function of
CPf1 by cloning the Francisella novicida cpf1 (FnCpf1),
cas genes operon and CRSIPR array into Escherichia coli.
During interference in type I and II CRISPR-Cas systems,
target interrogation is initiated by searching for a proto-
spacer adjacent motif (PAM), after which target recogni-
tion is completed by base-pairing between the crRNA and
the protospacer. By screening for interference against a
plasmid library containing variable PAMs, Zetsche et al.
[4] were able to identify the PAM requirements for
FnCpf1 (5′-TTN-3′ and 5′-CTA-3′ on the displaced
strand), and in doing so provided the first evidence that
type V systems are genuine CRISPR-Cas systems. Fif-
teen other Cpf1-family proteins displayed a similar 5′-
TTN-3′ or 5′-TTTN-3′ PAM selectivity [4]. Surpris-
ingly, the PAM for Cpf1 is on the opposite end of the
protospacer when compared with that for Cas9, yet is
similar to that for the class 1, type I systems. Further-
more, most Cas9 proteins have a G-rich PAM prefer-
ence; the PAM for the well-characterized Streptococcus
pyogenes Cas9 (SpCas9) is 5′-NGG-3′ [6]. Although
PAM selectivity limits interference targets, the PAM
repertoire can be expanded by utilizing Cas9 orthologs
[8, 9] or by engineering Cas9 variants to recognize
other PAMs and reduce off-target cleavage [10]. Cpf1
further extends the potential targets utilized by existing
Cas9 proteins and might be useful for manipulation of
A/T-rich genomes [4].A major difference between Cas9 and Cpf1 proteins is
that Cpf1 does not utilize tracrRNA, and thus requires
only a crRNA (Fig. 1). The FnCpf1 crRNAs are 42–44 nu-
cleotides long (19-nucleotide repeat and 23–25-nucleotide
spacer) and contain a single stem-loop, which tolerates
sequence changes that retain secondary structure [4].
The Cpf1 crRNAs are significantly shorter than the
~100-nucleotide engineered sgRNAs required by Cas9,
and thereby offering cheaper and simpler guide RNA
production. Furthermore, the different sgRNA and crRNA
requirements of Cas9 and Cpf1 will allow both systems to
be combined when multiplexing of different targets is de-
sired — for example, when genome editing is combined
with gene regulation. Multiplexing is possible using or-
thogonal Cas9s that have different sgRNA sequence speci-
ficities, and Cpf1 will expand this potential [8, 9].
For efficient interference by Cpf1, the spacer-encoded
portion of the crRNA requires a minimum of 18 nucleo-
tides and a seed sequence in the first ~5 nucleotides of
the 5′ end of the spacer. Seed sequences are always
present adjacent to the PAM; therefore, in Cpf1 the seed
sequence is at the opposite end of the protospacer to
that in Cas9. Although both Cas9 and Cpf1 make DSBs,
Cas9 uses its RuvC- and HNH-like domains to make
blunt-ended cuts within the seed, whereas Cpf1 uses a
RuvC-like domain to produce staggered cuts outside of
the seed (Fig. 1) [4]. As discussed below, these differences
have significant implications for the biotechnological
application of Cpf1.
Zetsche and colleagues tested whether Cpf1 could per-
form genome editing in human cells [4]. Eight different
Cpf1 proteins were tested and all cleaved DNA in vitro,
but only two proteins from the Acidaminococcus and
Lachnospiraceae genera yielded detectable insertion/de-
letion (indel) mutations in vivo at levels similar to those
produced by SpCas9. It is proposed that the differences
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offers the biggest potential benefit for genome editing.
Two major mechanisms are used during genome editing
to repair DSBs: non-homologous end-joining (NHEJ)
and homology-directed repair (HDR). In the case of
Cas9, error-prone NHEJ is dominant and results in
indels that will disrupt the Cas9 target site and impede
HDR. Because Cpf1 makes staggered cuts away from the
critical seed region, NHEJ will not disrupt the target site,
therefore ensuring that Cpf1 can continue to cut the
same site until the desired HDR recombination event
has taken place. This potential benefit requires confirm-
ation in future studies.
Type V CRISPR-Cas systems
In addition to offering potential advances in genome
editing, Cpf1 has begun to provide fascinating insights
and questions regarding the biology of type V CRISPR-
Cas systems. Interestingly, the type V (class 2) systems
share common features with class 1 systems. There are
currently no data on spacer acquisition by type V sys-
tems, but the type V Cas1 and Cas2 (and Cas4) adapta-
tion proteins are more evolutionarily related to type I
and III (class 1) proteins [5], suggesting that spacer ac-
quisition by type V systems has more similarities to that
in class 1 systems than to that in class 2 systems. For
crRNA biogenesis, type II systems need Cas9, tracrRNA
and host RNaseIII. RNA sequencing in F. novicida and
in E. coli containing only Cpf1 and the CRISPR array re-
vealed similar crRNA profiles [4]. Although it is possible
that a host ribonuclease is involved, crRNA generation
seems to require only Cpf1. Interference by type V systems
also has features that are reminiscent of type I systems.
Indeed, the PAM and seed are in the same location as in
type I systems and the PAM is similar to the most com-
mon one in E. coli type I-E (5′-TTN-3′ compared with
5′-TTC-3′). A full in vivo seed analysis is required to
understand interference specificity, which will be import-
ant for genome-editing applications.
Within the recent CRISPR-Cas classification [5], the
only systems that have not been characterized experimen-
tally are type IV members of class 1. Type IV systems are
likely to form multi-protein complexes, but they do not
appear to be associated with cas1 and cas2 or with
CRISPR arrays, raising intriguing questions about their
mode of action. From this recent study from the Zhang
laboratory, it is evident that Cpf1 offers new avenues for
biotechnological exploitation. Undoubtedly, the analysis of
other CRISPR-Cas systems will continue to provide fur-
ther tools for molecular biology.
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